Five Prime Therapeutics Inc (FPRX.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|67||2016||Chairman of the Board, President, Chief Executive Officer|
|61||2013||Chief Financial Officer, Senior Vice President|
|47||2016||Chief Operating Officer, Director|
|56||2016||Senior Vice President, Development Sciences|
|54||2017||Senior Vice President and Chief Medical Officer|
- BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors
- BRIEF-Five Prime posts Q3 loss of $1.54 per share
- BRIEF-Five Prime Therapeutics appoints Aron Knickerbocker as CEO
- BRIEF-Five Prime to feature two oral data presentations at ESMO congress
- BRIEF-Five Prime Therapeutics delivered to Inhibrx written notice of termination of agreement